Correlation between in vitro cyclic adenosine monophosphate phosphodiesterase inhibition and in vivo anti-inflammatory effect

Skin Pharmacology and Applied Skin Physiology

Volumn 13, Issue 2, 2000, Pages 86-92

  Goyarts, Earl ^a   Mammone, Thomas ^a   Muizzuddin, Neelam ^a   Marenus, Ken ^a   Maes, Daniel ^a  

^a Estee Lauder Inc   (United States)

Author keywords

Anti inflammatory effect; Balsam of Peru; Phosphodiesterase; Phosphodiesterase inhibitors

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIINFLAMMATORY AGENT; BALSAM PERU; CAFFEINE; CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHEMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034128487     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029912     Document Type: Article

References (22)

1. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995;75:725-741.
2. Grewe S, Chan SC, Hanifin JM: Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982;70:452-457.
3. Engels P, Fichtel K, Lubbert H: Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994;350:291-295.
4. Nicholson CD, Challis RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991; 12:19-27.
5. Tenor H, Hatzelmann A, Wendel A, Schudt C: Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate-dependent up-regulation in a human keratinocyte cell line (HaCaT). J Invest Dermatol 1995;105:70-74.
6. Chujor SN, Hammerschmid F, Lam C: Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermal cell lines. J Invest Dermatol 1998;110:287-291.
7. Chan SC, Reifsnyder D, Beavo J, Hanifin JM: Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993;91: 1179-1188.
8. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, Weiner ES: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-56.
9. Schwarz A, Krone C, Trautinger F, Aragane Y, Neuner P, Luger TA, Schwarz T: Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 1993;101:549-552.
10. Balato N, Patruno C, Lembo G, Cuccurullo FM, Ayala F: Effect of pentoxifylline on patch test response. Contact Dermatitis 1996; 34:153.
11. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ: Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular form of the enzyme. Adv Cyclic Nucleotide Res 1979;10:69-92.
12. Muizzuddin N, Marenus KD, Maes DH: Use of a Chromameter in assessing the efficacy of anti-irritants and tanning accelerators. J Soc Cosmet Chem 1990;41:269-278.
13. Bernadi L, Berardesca E: Measurement of skin blood flow by laser-Doppler flowmetry; in Berardesca E, Elsner P, Wilhelm KP, Maibach HI (eds): Methods and Instrumentation. Boca Raton, CRC Press, 1995, pp 13-28.
14. Matthies C, Dooms-Goosen A, Lachapelle JM, Lahati A, Menne T, Whitt IR, Wilkinson J: Patch testing with fractionated Balsam of Peru. Am J Contact Dermatitis 1988;19: 384-385.
15. Burdick AE, Mathias CGT: The Contact Urticaria Syndrome. Dermatol Clin 1985;3:71-84.
16. Lahti A, von Krogh G, Maibach HI: Contact Urticaria Syndrome. An expanding phenomenon; in Stone J (ed): Dermatologic Immunology and Allergy. St Louis, Mosby, 1985, pp 379-390.
17. Forsbeck M, Skog E: Immediate reactions to patch tests with Balsam of Peru. Contact Dermatitis 1977;3: 201-205.
18. Lahti A, Vaananen A, Kokkonen EL, Hannuksela M: Acetyl salicylic acid inhibits non-immunogenic contact urticaria. Contact Dermatitis 1987;16:133-135.
19. Lahti A: Terfenadine does not inhibit non-immunogenic contact urticaria. Contact Dermatitis 1987;16: 220-223.
20. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor DJ, Furdon PJ: Differential regulation of human monocyte-drived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995;272: 1313-1320.
21. Endres S, Fulle HJ, Sinha B, Stoll D, Dinarello CA, Grezer R, Weber PC: Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 1991;72:56-60.
22. Sekut L, Yarnall D, Stimpson SA: Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic inflammation. Clin Exp Immunol 1995;100:126-132.